You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

~ Buy the SEGLENTIS (celecoxib; tramadol hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

SEGLENTIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Seglentis patents expire, and when can generic versions of Seglentis launch?

Seglentis is a drug marketed by Kowa Pharms and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and five patent family members in thirty-five countries.

The generic ingredient in SEGLENTIS is celecoxib; tramadol hydrochloride. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the celecoxib; tramadol hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Seglentis

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 19, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SEGLENTIS?
  • What are the global sales for SEGLENTIS?
  • What is Average Wholesale Price for SEGLENTIS?
Summary for SEGLENTIS
International Patents:105
US Patents:7
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for SEGLENTIS
What excipients (inactive ingredients) are in SEGLENTIS?SEGLENTIS excipients list
DailyMed Link:SEGLENTIS at DailyMed
Drug patent expirations by year for SEGLENTIS
Drug Prices for SEGLENTIS

See drug prices for SEGLENTIS

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SEGLENTIS
Generic Entry Date for SEGLENTIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SEGLENTIS

SEGLENTIS is protected by seven US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLENTIS is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SEGLENTIS

Co-crystals of tramadol and coxibis
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Co-crystals of tramadol and coxibs
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting SEGLENTIS

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Kowa Pharms SEGLENTIS celecoxib; tramadol hydrochloride TABLET;ORAL 213426-001 Oct 15, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SEGLENTIS

When does loss-of-exclusivity occur for SEGLENTIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9008
Patent: CO-CRISTALES DE TRAMADOL Y COXIBS, PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 09304235
Patent: Co-crystals of tramadol and NSAIDs
Estimated Expiration: ⤷  Sign Up

Patent: 10306168
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0920358
Patent: cocristais de tramadol e insaids
Estimated Expiration: ⤷  Sign Up

Patent: 2012005011
Patent: cocristais de tramadol e coxibis
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 37754
Patent: CO-CRISTAUX DE TRAMADOL ET D'AINS (CO-CRYSTALS OF TRAMADOL AND NSAIDS)
Estimated Expiration: ⤷  Sign Up

Patent: 71665
Patent: CO-CRISTAUX DE TRAMADOL ET DE COXIBS (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷  Sign Up

China

Patent: 2186465
Patent: Co-crystals of tramadol and nsaids
Estimated Expiration: ⤷  Sign Up

Patent: 2573825
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷  Sign Up

Patent: 4817501
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Patent: 4844513
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 11248
Patent: COCRISTALES DE TRAMADOL Y COXIBS
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0130316
Estimated Expiration: ⤷  Sign Up

Patent: 0161526
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 13956
Estimated Expiration: ⤷  Sign Up

Patent: 18374
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 49238
Estimated Expiration: ⤷  Sign Up

Patent: 88169
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 12011734
Patent: COCRISTALES DE TRAMADOL Y COXIBS
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 77215
Patent: Co-cristaux de tramadol et NSAID (Co-crystals of tramadol and NSAIDs)
Estimated Expiration: ⤷  Sign Up

Patent: 49238
Patent: CO-CRISTAUX DE TRAMADOL ET NSAID (CO-CRYSTALS OF TRAMADOL AND NSAIDS)
Estimated Expiration: ⤷  Sign Up

Patent: 88169
Patent: CO-CRISTAUX DE TRAMADOL ET NSAID (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷  Sign Up

Patent: 86432
Patent: Co-cristaux de Tramadol et NSAID tels que des Coxibs (Co-crystals of Tramadol and NSAIDs like Coxibs)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 73380
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 30976
Estimated Expiration: ⤷  Sign Up

India

Patent: 35DEN2012
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 1785
Patent: קו-גבישים של טרמדול ונפרוקסן (Co-crystals of tramadol and naproxen)
Estimated Expiration: ⤷  Sign Up

Patent: 8256
Patent: קו-גביש של טרמדול הידרוכלוריד רצמי וסלקוקסיב (Co-crystal of (rac) tramadol hcl and celecoxib)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 99564
Estimated Expiration: ⤷  Sign Up

Patent: 45830
Estimated Expiration: ⤷  Sign Up

Patent: 12505847
Estimated Expiration: ⤷  Sign Up

Patent: 13507402
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 49238
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 6285
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 6318
Patent: CO-CRISTALES DE TRAMADOL Y NSAIDS. (CO-CRYSTALS OF TRAMADOL AND NSAIDS.)
Estimated Expiration: ⤷  Sign Up

Patent: 11003612
Patent: CO-CRISTALES DE TRAMADOL Y NSAIDS. (CO-CRYSTALS OF TRAMADOL AND NSAIDS.)
Estimated Expiration: ⤷  Sign Up

Patent: 12003050
Patent: CO-CRISTALES DE TRAMADOL Y COXIBS. (CO-CRYSTALS OF TRAMADOL AND COXIBS.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 742
Patent: بلورات متعددة ترامادول و كوكسيب
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 1873
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDS
Estimated Expiration: ⤷  Sign Up

Patent: 8353
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 49238
Estimated Expiration: ⤷  Sign Up

Patent: 88169
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 49238
Estimated Expiration: ⤷  Sign Up

Patent: 88169
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 47830
Patent: СОКРИСТАЛЛЫ ТРАМАДОЛА И КОКСИБОВ (CO-CRYSTALS OF TRAMADOL AND COXIBS)
Estimated Expiration: ⤷  Sign Up

Patent: 99717
Patent: СОКРИСТАЛЛИЧЕСКИЕ ФОРМЫ ТРАМАДОЛА И NSAID (CO-CRYSTALLINE FORMS OF TRAMADOL AND NSAID)
Estimated Expiration: ⤷  Sign Up

Patent: 11119608
Patent: СОКРИСТАЛЛИЧЕСКИЕ ФОРМЫ ТРАМАДОЛА И NSAID
Estimated Expiration: ⤷  Sign Up

Patent: 12120088
Patent: СОКРИСТАЛЛЫ ТРАМАДОЛА И КОКСИБОВ
Estimated Expiration: ⤷  Sign Up

San Marino

Patent: 01300048
Patent: Cocristalli di tramadol e inibitori della cox-2
Estimated Expiration: ⤷  Sign Up

Patent: 01600439
Patent: CO-CRISTALLI DI TRAMADOLO E NSAID
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 8835
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 49238
Estimated Expiration: ⤷  Sign Up

Patent: 88169
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1102762
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDs
Estimated Expiration: ⤷  Sign Up

Patent: 1201892
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1471585
Estimated Expiration: ⤷  Sign Up

Patent: 1679400
Estimated Expiration: ⤷  Sign Up

Patent: 110069860
Patent: CO-CRYSTALS OF TRAMADOL AND NSAIDS
Estimated Expiration: ⤷  Sign Up

Patent: 120099212
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 02112
Estimated Expiration: ⤷  Sign Up

Patent: 03962
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 41630
Estimated Expiration: ⤷  Sign Up

Patent: 1116273
Patent: Co-crystals of tramadol and coxibs
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 12000075
Patent: CO-CRYSTALS OF TRAMADOL AND COXIBS
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 9534
Patent: СПІВКРИСТАЛИ ТРАМАДОЛУ І КОКСИБІВ (TRAMADOL AND COXIBES COCRYSTALLS)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SEGLENTIS around the world.

Country Patent Number Title Estimated Expiration
Lithuania 2349238 ⤷  Sign Up
Australia 2009304235 Co-crystals of tramadol and NSAIDs ⤷  Sign Up
Portugal 2575778 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SEGLENTIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0731795 10075033 Germany ⤷  Sign Up PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.